Your browser doesn't support javascript.
loading
Prostate cancer survival in South West Victoria.
Chilko, Natalie; Dean, Samantha; Matheson, Leigh M; Grills, Richard; Davidson, Adee J; Kearns, Paul; Campbell, David; Rogers, Margaret J; Collins, Ian M.
Affiliation
  • Chilko N; Barwon Health, Geelong, Victoria, Australia.
  • Dean S; Albury Wodonga Regional Cancer Centre, East Albury, New South Wales, Australia.
  • Matheson LM; Southwest Healthcare, Warrnambool, Victoria, Australia.
  • Grills R; Barwon South Western Regional Integrated Cancer Service, Geelong, Victoria, Australia.
  • Davidson AJ; Department of Surgery, Deakin University, Geelong, Victoria, Australia.
  • Kearns P; Department of Urological Surgery, Barwon Health, Geelong, Victoria, Australia.
  • Campbell D; Specialised Urology Group, Warrnambool, Victoria, Australia.
  • Rogers MJ; Barwon Health, Geelong, Victoria, Australia.
  • Collins IM; Andrew Love Cancer Centre, Barwon Health, Geelong, Victoria, Australia.
Aust J Rural Health ; 30(5): 676-682, 2022 Oct.
Article in En | MEDLINE | ID: mdl-35605157
ABSTRACT

OBJECTIVE:

To explore reasons for survival disparities for patients with prostate cancer in the Barwon South West area of Victoria. DESIGN, SETTING AND

PARTICIPANTS:

We have described incidence, diagnostics, treatment pathways, and survival for four regions of the Barwon South Western Victoria. Analysis included all newly diagnosed prostate cancer patients from 2009 to 2015 in the Evaluation of Cancer Outcomes Barwon South West Registry. Regions included 1 Queenscliffe 2 Geelong, Colac Otway and Corangamite 3 Moyne, Warrnambool and Southern Grampians and 4 Glenelg. Across the four regions, variables were compared using a chi square statistic or analysis of variance and survival data was assessed with the Kaplan-Meier curves. MAIN OUTCOME

MEASURES:

Incidence, treatment pathways and survival for prostate cancer patients.

RESULTS:

A total of 1776 patients were diagnosed with prostate cancer from 2009 to 2015 in the Barwon South West area. In regions 1-4, there were 298 (1.04%), 1085 (0.92%), 273 (0.97%) and 120 (1.2%) cases, respectively. There was no significant difference in Gleason score and treatment. The 5-year survival rate was 85%, 76%, 71% and 80%, respectively, as compared with the national average of 95%. PSA scores >20 ng/ml at diagnosis, as a surrogate for high-risk disease, occurred in 23%, 29%, 22% and 21%, respectively (p < 0.01). The proportions presenting with stage IV disease were 17%, 26%, 21% and 6%, respectively (p = 0.10).

CONCLUSION:

Men diagnosed with prostate cancer in South West Victoria have a considerably lower 5-year survival compared with the national average with later disease at presentation in some areas.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Prostate-Specific Antigen Type of study: Incidence_studies / Prognostic_studies Limits: Humans / Male Country/Region as subject: Oceania Language: En Journal: Aust J Rural Health Journal subject: ENFERMAGEM / SAUDE PUBLICA Year: 2022 Type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Prostate-Specific Antigen Type of study: Incidence_studies / Prognostic_studies Limits: Humans / Male Country/Region as subject: Oceania Language: En Journal: Aust J Rural Health Journal subject: ENFERMAGEM / SAUDE PUBLICA Year: 2022 Type: Article Affiliation country: Australia